5-treatment, 5-way crossover study in GERD patients.¹

Source: Data on File, DA-NEX-26 ¹

• Data from a randomized, open-label, comparative, 5-treatment, 5-way crossover study comparing mean pharmacodynamic parameters in patients with GERD treated for 5 days with at least a 10-day washout period.
  *NEXIUM 20 mg was not evaluated in this study.
  †All pair-wise comparisons vs NEXIUM.
  ‡Manufactured by AstraZeneca, Södertälje, Sweden.

The clinical relevance of these ph data has not been established.

The most frequently reported adverse events with NEXIUM are headache, diarrhea, and abdominal pain. Symptomatic response to therapy does not preclude the presence of gastric malignancy. As with all PPIs, patients treated concomitantly with warfarin may need to be monitored for increases in INR and prothrombin time.

NEXIUM should be used only for the conditions, dosages, and durations specified in the Prescribing Information. Before prescribing NEXIUM, please see accompanying full Prescribing Information

References: 1. Data on file, DA-NEX-26. 2. Data on file, DA-NEX-33. 3. Data on file, DA-NEX-34. 4. Data on file, DA-NEX-31. 5. Prescribing Information for NEXIUM. 6. Castell DO, Kahrilas PJ, Richter JE, et al. Am J Gastroenterol. 2002;97:575-583. 7. Richter JE, Kahrilas PJ, Johanson J, et al. Am J Gastroenterol. 2001;96:656-665. 8. Kahrilas PJ, Falk GW, Johnson DA, et al. Aliment Pharmacol Ther. 2000;14:1249-1258. 9. Lauritsen K, Devière J, Bigard M-A, et al. Aliment Pharmacol Ther. 2003;17:333- 341. 10. Johnson DA, Benjamin SB, Vakil NB, et al. Am J Gastroenterol. 2001;96:27-34. 11. Vakil NB, Shaker R, Johnson DA, et al. Aliment Pharmacol Ther. 2001;15:927-935. 12. Data on file, DA-NEX-18. 13. Data on file, DA-NEX-32.